Most
phenotypic screens aiming to discover new antimalarial chemotypes
begin with low cost, high-throughput tests against the asexual blood
stage (ABS) of the malaria parasite life cycle. Compounds active against
the ABS are then sequentially tested in more difficult assays that
predict whether a compound has other beneficial attributes. Although
applying this strategy to new chemical libraries may yield new leads,
repeated iterations may lead to diminishing returns and the rediscovery
of chemotypes hitting well-known targets. Here, we adopted a different
strategy to find starting points, testing ∼70,000 open source
small molecules from the Global Health Chemical Diversity Library
for activity against the liver stage, mature sexual stage, and asexual
blood stage malaria parasites in parallel. In addition, instead of
using an asexual assay that measures accumulated parasite DNA in the
presence of compound (SYBR green), a real time luciferase-dependent
parasite viability assay was used that distinguishes slow-acting (delayed
death) from fast-acting compounds. Among 382 scaffolds with the activity
confirmed by dose response (<10 μM), we discovered 68 novel
delayed-death, 84 liver stage, and 68 stage V gametocyte inhibitors
as well. Although 89% of the evaluated compounds had activity in only a single
life cycle stage, we discovered six potent (half-maximal inhibitory
concentration of <1 μM) multistage scaffolds, including a
novel cytochrome bc1 chemotype. Our data further show the luciferase-based
assays have higher sensitivity. Chemoinformatic analysis of positive
and negative compounds identified scaffold families with a strong
enrichment for activity against specific or multiple stages.